Abstract

New research on pharmaceutical-industry sponsorship of clinical research in breast cancer shows that treatment trials funded by the industry are more likely to show positive results than studies sponsored by other sources. There are also major differences in trial design when drug companies are the funders.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call